Essa Pharma
Investors/Media

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

Latest News
Oct 31, 2024

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility...

Sep 13, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...

Sep 11, 2024

ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the...

View All News

Stock Performance

Last Price


Change


Volume

NASDAQEPIX

Investor & Media Contacts

Investor Contact
Argot Partners
essa@argotpartners.com

Media Contact
Argot Partners
essa@argotpartners.com